Du Yuan-Yuan, Yang Hao, Chen Cheng-Cheng, He Zi-Yan
Department of Rehabilitation Medicine, the 901st Hospital of the Joint Logistics Support Force of PLA, Hefei 230000, Anhui, China.
Zhongguo Gu Shang. 2024 Jul 25;37(7):684-8. doi: 10.12200/j.issn.1003-0034.20230836.
To investigate the changes and clinical significance of NOD like receptor protein 3 (NLRP3) inflammasomes and related factors in patients with spinal fractures complicated with acute spinal cord injury (SCI).
Eighty-six spinal fracture patients complicated with acute SCI admitted to hospital from June 2019 to March 2022 were selected as SCI group, There were 48 males and 38 females, with an average age of (43.48±6.58) years old. And 100 healthy volunteers who underwent physical examination during the same time were selected as control group, including 56 males patients and 44 females patients, with an average age of (45.13±6.43) years old. Peripheral blood mononuclear cell (PBMC) were collected, and the mRNA expressions of NLRP3 and Caspase-1 were detected. Serum was collected and the levels of interleukin (IL)- 1β, IL-18 were detected. According to Frankel's grade, the SCI group was divided into complete injury patients and incomplete injury patients, and according to the Japanese Orthopedic Society (JOA) grade, the SCI group was divided into good prognosis group and poor prognosis group. The difference of NLRP3, Caspase-1, IL-1β, IL-18 among groups were compared, the influencing factors for poor prognosis in SCI patients was analyzed by Logistic regression.
The mRNA expression levels of NLRP3 (1.41±0.33) and Caspase-1 (1.44±0.35) in PBMC and the levels of IL-1β(45.34±13.22) pg·ml, IL-18(40.95±8.77) pg·ml in serum of SCI group were higher than those of the control group[(1.00±0.19), (1.00±0.16), (16.58±4.24) pg·ml, (12.57±3.68) pg·ml] (<0.05). The mRNA expression levels of NLRP3(1.63±0.34) and Caspase-1 (1.67±0.27) in PBMC and the levels of IL-1β(51.09±11.10) pg·ml, IL-18 (47.65±7.93) pg·ml in serum of patients with complete injury in the SCI group were higher than those of patients with incomplete injury [(1.31±0.27), (1.34±0.33), (42.85±13.36) pg·ml, (38.05±7.48) pg·ml](<0.05). The mRNA expression levels of NLRP3 (1.66±0.31) and Caspase-1 (1.72±0.31)in PBMC and the levels of IL-1β(51.21±11.31) pg·ml, IL-18 (45.70±7.25) pg·ml in serum, the proportion of complete injury(21 patients), and the proportion of spinal cord edema or bleeding of patients(15 patients) with poor prognosis in the SCI group were higher than those of patients with good prognosis[(1.28±0.26), (1.37±0.36), (42.79±13.25) pg·ml、(38.90±8.63) pg·ml, 5、20 cases](<0.05). Complete injury and the mRNA expression of NLRP3 in PBMC were the influencing factors for poor prognosis in the SCI group (<0.05).
The activation of NLRP3 inflammasomes in patients with spinal fractures complicated with acute SCI is associated with worsening injury and poor prognosis, and NLRP3 expression can serve as a marker for evaluating prognosis.
探讨脊髓骨折合并急性脊髓损伤(SCI)患者中NOD样受体蛋白3(NLRP3)炎性小体及相关因子的变化及其临床意义。
选取2019年6月至2022年3月收治的86例脊髓骨折合并急性SCI患者作为SCI组,其中男性48例,女性38例,平均年龄(43.48±6.58)岁。同期选取100例接受体检的健康志愿者作为对照组,其中男性患者56例,女性患者44例,平均年龄(45.13±6.43)岁。采集外周血单个核细胞(PBMC),检测NLRP3和半胱天冬酶-1(Caspase-1)的mRNA表达。采集血清,检测白细胞介素(IL)-1β、IL-18水平。根据Frankel分级,将SCI组分为完全损伤患者和不完全损伤患者;根据日本骨科协会(JOA)分级,将SCI组分为预后良好组和预后不良组。比较各组NLRP3、Caspase-1、IL-1β、IL-18的差异,采用Logistic回归分析SCI患者预后不良的影响因素。
SCI组PBMC中NLRP3(1.41±0.33)和Caspase-1(1.44±0.35)的mRNA表达水平及血清中IL-1β(45.34±13.22)pg·ml、IL-18(40.95±8.77)pg·ml水平均高于对照组[(1.00±0.19)、(1.00±0.16)、(16.58±4.24)pg·ml、(12.57±3.68)pg·ml](P<0.05)。SCI组中完全损伤患者PBMC中NLRP3(1.63±0.34)和Caspase-1(1.67±0.27)的mRNA表达水平及血清中IL-1β(51.09±11.10)pg·ml、IL-18(47.65±7.93)pg·ml水平均高于不完全损伤患者[(1.31±0.27)、(1.34±0.33)、(42.85±13.36)pg·ml、(38.05±7.48)pg·ml](P<0.05)。SCI组中预后不良患者PBMC中NLRP3(1.66±0.31)和Caspase-1(1.72±0.31)的mRNA表达水平及血清中IL-1β(51.21±11.31)pg·ml、IL-18(45.70±7.25)pg·ml水平、完全损伤比例(21例)及脊髓水肿或出血比例(15例)均高于预后良好患者[(1.28±0.26)、(1.37±0.36)、(42.79±13.25)pg·ml、(38.90±8.63)pg·ml、5、20例](P<0.05)。完全损伤及PBMC中NLRP3的mRNA表达是SCI组预后不良的影响因素(P<0.05)。
脊髓骨折合并急性SCI患者中NLRP3炎性小体的激活与损伤加重及预后不良有关,NLRP3表达可作为评估预后的指标。